NCT04185038View on ClinicalTrials.gov

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2041

Conditions

Central Nervous System TumorDiffuse Intrinsic Pontine GliomaDiffuse Midline GliomaEpendymomaMedulloblastoma, ChildhoodGerm Cell TumorAtypical Teratoid/Rhabdoid TumorPrimitive Neuroectodermal TumorChoroid Plexus CarcinomaPineoblastoma, ChildhoodGlioma

Interventions

BIOLOGICAL

SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel

Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter

Trial Locations (1)

98105

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors

lead

Seattle Children's Hospital

OTHER

NCT04185038 - Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Biotech Hunter | Biotech Hunter